A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure - ASTRONAUT

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure - ASTRONAUT

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Decompensated heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms ASTRONAUT
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Nov 2017 Results assessing clinical outcomes, plasma renin activity published in the European Journal of Heart Failure.
    • 15 Nov 2017 Results of pre-specified neurohormonal substudy, presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top